Paper37720177
SEPTIN3 Promotes Progression of Triple-Negative Breast Cancer via Activating Wnt Pathway.
Wang GZ and 2 others. Int J Gen Med, 2023. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. SEPTIN3 Promotes Progression of Triple-Negative Breast Cancer via Activating Wnt Pathway. Papers, record 37720177. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37720177
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SEPTIN3 Promotes Progression of Triple-Negative Breast Cancer via Activating Wnt Pathway.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27939063 | Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. | Lancet | 2017 | https://conductscience.org/library/papers/27939063 | PubMed |
| 2 | 35714673 | Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 | https://conductscience.org/library/papers/35714673 | PubMed |
| 3 | 26711338 | Cdc42EP3/BORG2 and Septin Network Enables Mechano-transduction and the Emergence of Cancer-Associated Fibroblasts. | Cell Rep | 2015 | https://conductscience.org/library/papers/26711338 | PubMed |
| 4 | 26771021 | The Molecular Signatures Database (MSigDB) hallmark gene set collection. | Cell Syst | 2015 | https://conductscience.org/library/papers/26771021 | PubMed |
| 5 | 33234169 | Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. | Mol Cancer | 2020 | https://conductscience.org/library/papers/33234169 | PubMed |
| 6 | 25033833 | Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. | Mol Cancer | 2014 | https://conductscience.org/library/papers/25033833 | PubMed |
| 7 | 26590424 | Post-transcriptional Wnt Signaling Governs Epididymal Sperm Maturation. | Cell | 2015 | https://conductscience.org/library/papers/26590424 | PubMed |
| 8 | 32803712 | Triple-negative breast cancer: new treatment strategies in the era of precision medicine. | Sci China Life Sci | 2021 | https://conductscience.org/library/papers/32803712 | PubMed |
| 9 | 34035258 | INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer. | Nat Commun | 2021 | https://conductscience.org/library/papers/34035258 | PubMed |
| 10 | 12727837 | The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. | Cancer Res | 2003 | https://conductscience.org/library/papers/12727837 | PubMed |
| 11 | 15485489 | Septin 3 (G-septin) is a developmentally regulated phosphoprotein enriched in presynaptic nerve terminals. | J Neurochem | 2004 | https://conductscience.org/library/papers/15485489 | PubMed |
| 12 | 35932293 | Neuronal-specific septin-3 binds Atg8/LC3B, accumulates and localizes to autophagosomes during induced autophagy. | Cell Mol Life Sci | 2022 | https://conductscience.org/library/papers/35932293 | PubMed |
| 13 | 36038913 | Recent advances in therapeutic strategies for triple-negative breast cancer. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/36038913 | PubMed |
| 14 | 36239657 | Pembrolizumab in Triple-Negative Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36239657 | PubMed |
| 15 | 35205681 | Classification of Breast Cancer Nottingham Prognostic Index Using High-Dimensional Embedding and Residual Neural Network. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35205681 | PubMed |
| 16 | 30670682 | Septin filament coalignment with microtubules depends on SEPT9_i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel. | Cell Death Dis | 2019 | https://conductscience.org/library/papers/30670682 | PubMed |
| 17 | 34901034 | Septin Assembly and Remodeling at the Cell Division Site During the Cell Cycle. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34901034 | PubMed |
| 18 | 17564677 | Targeted disruption of Sept3, a heteromeric assembly partner of Sept5 and Sept7 in axons, has no effect on developing CNS neurons. | J Neurochem | 2007 | https://conductscience.org/library/papers/17564677 | PubMed |
| 19 | 19088017 | Triple-negative breast cancer: risk factors to potential targets. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/19088017 | PubMed |
| 20 | 34518209 | WNT as a Driver and Dependency in Cancer. | Cancer Discov | 2021 | https://conductscience.org/library/papers/34518209 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42310796 | Hypoxia and lactate metabolism-related gene COL5A3 promotes triple negative breast cancer progression via DDR1/FAK/PI3K/AKT pathway. | Biol Direct | 2026 | https://conductscience.org/library/papers/42310796 | PubMed |
| 41340014 | Revealing Causal Protein Biomarkers and Potential Therapeutic Targets for Histologic-Specific Lung Cancer. | J Cell Mol Med | 2025 | https://conductscience.org/library/papers/41340014 | PubMed |
| 40313394 | Construction of a novel five programmed cell death-related gene signature as a promising prognostic model for triple negative breast cancer. | PeerJ | 2025 | https://conductscience.org/library/papers/40313394 | PubMed |
Genes17
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37720177
GET https://conductscience.org/api/papers/v1/37720177/references?page=2